Advertisement

Clinical Rheumatology

, Volume 13, Issue 3, pp 427–432 | Cite as

Clinical correlation of anticentromere antibodies

  • M. Zuber
  • R. Gotzen
  • I. Filler
Bookreviews Originals

Summary

A retrospective survey of all patients with a positive anticentromere antibody (ACA) determination was undertaken over a 3-years period of time in a university hospital. Forty-five patients were positive for anticentromere antibodies. The analysis of the clinical characteristics and diagnoses of the patients with anticentromere antibodies were correlated and showed a diverse array of symptoms. Only 4.4% had CREST syndrome, 6.7% had limited scleroderma, 17.8% had diffuse scleroderma, 20% had other connective tissue diseases, 20% had other miscellaneous rheumatic conditions, 11.1% had tumours and 20% other nonrheumatic diseases. The study shows that the presence of ACA, as detected during routine ANA-testing, does not strongly suggest a diagnosis of CREST at that time. The presence of a scleroderma-variant in almost 50% of the patients and the occurrence of Raynaud's phenomenon in 62% underscores, however, an association of ACA with (early) scleroderma-like disorders.

Key words

Anticentromere Antibodies Antinuclear Antibodies Autoantibodies CREST Syndrome Scleroderma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tan, E.M. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989, 44, 93–151.Google Scholar
  2. 2.
    Tan, E.M., Chan, E.K.L., Sullivan, K.F., Rubin, R.I. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopath 1988, 47, 121–141.Google Scholar
  3. 3.
    Moroi, Y., Peebles, C., Fritzler, M.J., Steigerwald, J., Tan, E.M. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980, 77, 1627–1631.Google Scholar
  4. 4.
    Tan, E.M., Rodnan, G.P., Garcia, I., Moroi, Y., Fritzler, M.J., Peebles, C. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980, 23, 617–625.Google Scholar
  5. 5.
    Fritzler, M.J., Kinsella, T.D., Garbutt, E. The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med 1980, 69, 520–526.Google Scholar
  6. 6.
    McCarty, G.A., Rice, J.R., Bembe, M.L., Barada, Jr. Fa. Anticentromere antibody. Clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum 1983, 26, 1–7.Google Scholar
  7. 7.
    Powell, F.A., Winkelmann, R.K., Venencie-Lemarchand, F., Spurbeck, J.L., Schroeter A.L. The anticentromere antibody. Disease specificity and clinical significance. Mayo Clin Proc 1984, 59, 700–706.Google Scholar
  8. 8.
    Chorzelski, T.P., Jablonska, S., Beutner, E.H. et al. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermat 1985, 113, 381–389.Google Scholar
  9. 9.
    Weiner, E.S., Earnshaw, W.C., Senécal, J.L., Bordwell, B., Johnson, P., Rothfield, N.F. Clinical association of anticentromere antibodies and antibodies to topoisomerase I. Arthritis Rheum 1988, 31, 378–385.Google Scholar
  10. 10.
    Miller, M.H., Littlejohn, G.D., Davidson, A., Jones, B., Topliss, D.J. The clinical significance of the anticentromere antibody. Br J Rheum 1987, 26, 17–21.Google Scholar
  11. 11.
    Bernstein, R.M., Steigerwald, J.C., Tan, E.M. Association of antinuclear antibodies in progressive systemic sclerosis. Clin Exp Immunol 1982, 48, 43–51.Google Scholar
  12. 12.
    Tramposch, H.D., Smith, C.D., Senecal, J.L., Rothfield, N. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984, 27, 121–124.Google Scholar
  13. 13.
    Catoggio, L.J., Bernstein, R.M., Black, C.M., Hughes, G.R.V., Maddison P.J. Serologic markers in progressive systemic sclerosis. Clinical correlations. Ann Rheum Dis 1983, 42, 23–27.Google Scholar
  14. 14.
    Steen, V.D., Ziegler, G.L., Rodnan, G.P., Medsger, T.A. Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984, 27, 125–131.Google Scholar
  15. 15.
    Kallenberg, C.G., Pastoor, G.W., Wouda, A.A., The, T.H. Antinuclear antibodies in patients with Raynaud's phenomenon. Clinical significance of anticentromere antibodies. Ann Rheum Dis 1982, 41, 282–287.Google Scholar
  16. 16.
    Ruffatti, A., Peserica, A., Glorioso, S., et al. Anticentromere antibody in localized scleroderma. J Am Acad Dermatol 1986, 15, 637–642.Google Scholar
  17. 17.
    Ruffatti, A., Artifoni, L., Gloriosa, S., et al. Prevalence of anticentromere antibody in blood relatives of anticentromere positive patients. J Rheum 1985, 12, 940–943.Google Scholar
  18. 18.
    Kallenberg, C.G.M., Wouda, A.A., Hoet, M.H., Venrooij van, J.V. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six-year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988, 47, 634–641.Google Scholar
  19. 19.
    Seibold, J.R., Trontell, M.C. Anticentromere antibody and primary pulmonary hypertension. J Rheumat 1982, 9, 607–609.Google Scholar
  20. 20.
    Bernstein, R.M., Callender, M.E., Neuberger, J.M., Hughes, G.R.V., Williams, R. Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 1982, 41, 612–614.Google Scholar
  21. 21.
    Modena, V., Marengo, C., Amoroso, A., et al. Primary biliary cirrhosis and rheumatic diseases: a clinical, immunological and immunogenetical study. Clin Exp Rheum 1986, 4, 129–134.Google Scholar
  22. 22.
    Cassani, F., Bianchi, F.B., Lenzi, M., Volta, U., Pisi, E. Immunomorphological characterization of antinuclear antibodies in chronic liver diseases. J Clin Path 1985, 38, 801–805.Google Scholar
  23. 23.
    Wade, J.P., Sack, B., Schur, P.H. Anticentromere antibodies — Clinical correlates. J. Rheumatol 1988, 15, 1759–1763.Google Scholar
  24. 24.
    Haberhauer, G., Bröll, H. Drug-induced anticentromere antibody? Z Rheumatol 1989, 48, 99–100.Google Scholar
  25. 25.
    Mitchell, S.R., McCarty, G.A., Katz, P. Anticentromere antibody is not specific for connective tissue disease with a promising prognosis. Arthritis Rheum, 1985, 28, 1076–1077.Google Scholar
  26. 26.
    Medsger, Jr.T.A. Classification of systemic sclerosis. In: Systemic Sclerosis: Scleroderma. Eds.: Jayson MIV and Black CM, John Wiley and Sons LTD 1988, 1–6.Google Scholar
  27. 27.
    Masi, A.T., Rodnan, G.P., Medsger, T.A. Jr. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23, 581–590.Google Scholar
  28. 28.
    ILAR/IUIS International ANA Committee: Tan, E.M., Feltkamp, T.E.W., Alarcon-Segovia, D., et al. Reference reagents for antinuclear antibodies. Arthritis Rheum 1988, 31, 1331.Google Scholar
  29. 29.
    Gerbracht, D.D., Steen, V.D., Ziegler, G.L., Medsger, T.A. Jr., Rodnan, G.P. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum 1985, 28, 87–92.Google Scholar
  30. 30.
    Harper, F.E., Maricq, H.R., Turner, E., Lidman, R.W., Leroy, E.C. A prospective study of Raynaud's phenomenon and early connective tissue disease. Am J Med 1982, 72, 883–888.Google Scholar
  31. 31.
    Sarkozi, J., Bookman, A.A., Lee, P., Keystone, E.C., Fritzler, M.J. Significance of anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med 1987, 83, 893–898.Google Scholar
  32. 32.
    Shiel, W.C., Jason, M. The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist. J Rheum 1989, 16, 782–785.Google Scholar
  33. 33.
    Reimer, G. Autoantibodies against nuclear, nucleolar and mitochondrial antigens in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1990, 16, 169–183.Google Scholar
  34. 34.
    Jarzabek-Chorzelska, M., Blaszczyk, M., Kolacinska-Strasz, Z., et al. Are ACA and Scl-70 antibodies mutually exclusive? Br J Derm 1990, 122, 201–208.Google Scholar
  35. 35.
    Ruffatti, A., Calligaro, A., Ferri, C., et al. Association of anti-centromere and anti-Scl-70 antibodies in scleroderma. Report of two cases. J Clin Lab Immunol 1985, 16, 227–229.Google Scholar
  36. 36.
    McNeilage, L.J., Youngchaiyud, U., Whittingham, S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989, 32, 54–59.Google Scholar
  37. 37.
    Kipnes, R.J., Craft, J., Hardin, J.A. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. Arthritis Rheum 1990, 33, 1931–1936.Google Scholar
  38. 38.
    Hietarinta, M., Tertti, R., Lassila, O. A patient with systemic sclerosis, severe cytopenias and the simultaneous presence of anticentromere and anti-Scl-70 antibodies. Clin Exp Rheumat 1993, 11, 457–461.Google Scholar
  39. 39.
    Tolosa-Vilella, C., Ordi-Ros, J., Vilardell-Tarres, M., Selva-O'Callaghan, Jordana-Comajuncosa, R. Raynaud's phenomenon and positive antinuclear antibodies in a malignancy. Ann Rheum Dis 1990, 49, 935–936.Google Scholar
  40. 40.
    Zuber, M. Positive antinuclear antibodies in malignancies. Ann Rheum Dis 1992, 51, 573–574.Google Scholar

Copyright information

© Clinical Rheumatology 1994

Authors and Affiliations

  • M. Zuber
    • 1
  • R. Gotzen
    • 2
  • I. Filler
    • 2
  1. 1.German Research Center for RheumatologyBerlinGermany
  2. 2.Department of Internal MedicineSteglitz University Medical CenterBerlinGermany

Personalised recommendations